Safety and efficacy of long term esomeprazole therapy in Patients with healed erosive oesophagitis

• Published in: Drug safety 2001, Vol.24 (8), p.625-635
• Main Authors: MATON, Paul N, VAKIL, Nimish B, LEVINE, Jeffrey G, HWANG, Clara, SKAMMER, Wendy, LUNDBORG, Per
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents - administration & dosage; Anti-Ulcer Agents - therapeutic use; Biological and medical sciences; Biopsy; Digestive system; esomeprazole; Esomeprazole - administration & dosage; Esomeprazole - analogs & derivatives; Esomeprazole - therapeutic use; esophagitis; Esophagitis - prevention & control; Humans; Male; Medical sciences; Middle Aged; Pharmacology. Drug treatments; Treatment Outcome
• ISSN: 0114-5916
• DOI: 10.2165/00002018-200124080-00006

To evaluate the safety and tolerability of long term treatment with esomeprazole in patients with healed erosive oesophagitis, and to describe its efficacy in the maintenance of healing. US multicentre, noncomparative, nonblind study. 807 patients with endoscopically confirmed healed erosive oesophagitis. Patients received esomeprazole 40 mg once daily for up to 12 months. Adverse events and clinical laboratory tests were assessed over the study period. Endoscopy was performed at the final visit of the antecedent healing trials and at months 6 and 12 of the current safety trial; gastric biopsies were obtained at the initial visit of the healing trials and at the end of the safety trial. 80.9% of patients completed 6 months of treatment; 76.6% completed 12 months of treatment. There were no serious drug-related adverse events. Diarrhoea, abdominal pain, flatulence, and headache were the only treatment-related adverse events reported by >3% of patients. Mean changes in laboratory measures were generally small and not clinically meaningful. Plasma gastrin levels increased, as expected, and reached a plateau after 3 months. No changes in gastric histological scores were noted in the majority of patients. Evaluation of gastric biopsies revealed an overall decline in chronic inflammation and atrophy. Intestinal metaplasia findings remained essentially unchanged. Life table estimates of maintenance of healing were 93.7% [95% confidence interval (CI) 92.0 to 95.5%] at 6 months and 89.4% (95% CI 87.0 to 91.7%) at 12 months. Daily treatment with esomeprazole 40 mg for up to 1 year in patients with healed erosive oesophagitis was generally well tolerated and effective. No safety concerns arose.